Dr. Barbara Kinnaird has over 25 years of research and business experience primarily in the fields of point of care (POC) testing and in vitro diagnostics. Since joining Response Biomedical Corp. in August 2004, Dr. Kinnaird has held several key management positions including responsibilities for Product Development, Quality, Regulatory, Manufacturing and Sales. Dr. Kinnaird has consistently demonstrated her ability to deliver results from her areas of responsibility.
During Dr. Kinnaird’s tenure in these positions, she has lead teams to improve the product design control, operational efficiencies, gross margins and sales. Additionally under her direction, the Company obtained and maintain regulatory approvals to support sales in several global jurisdictions such as China, Japan, United States and Canada. Dr. Kinnaird’s strengths include her extensive experience in empowering a team to manage through organizational changes that improve the Company processes, decrease costs and accelerate business performance.
Dr. Kinnaird holds a Ph.D. in Microbiology and Immunology from the University of British Columbia at the B.C. Children’s Hospital in the Department of Pediatrics. She conducted her post-doctoral research at the Michael Smith Laboratories in genomics and gene expression profiling, in collaboration with the B.C. Genome Sciences Centre and consulted for the Proteomics division of Incyte Genomics Inc.
Bill Adams is a Chartered Accountant with over 30 years of strategic financial management experience in both public and private companies. Through the course of his career he has raised over $250 million in private and public debt and equity and has been instrumental in structuring and executing acquisitions totaling over $600 million. In addition to his capital markets experience, Mr. Adams brings a wealth of knowledge in driving change in complex commercial organizations as well as managing the challenges of both significant growth and financial restructuring.
Mr. Adams has broad experience in corporate governance as well as in managing the Finance, Investor Relations, Legal, Human Resources and Information Technology functions in multiple organizations. In addition, he has extensive business development experience having led or been a key member of teams that have completed multiple international licensing and development transactions. He was previously Chief Financial Officer of CellFor Inc., a privately-held forestry biotechnology company that was sold to a U.S. company in August 2012.
Prior to his position at CellFor, Mr. Adams was the Chief Financial Officer of the publicly-listed bio-pharmaceutical company AnorMED Inc. from its start up, to IPO, to NASDAQ listing and through to its successful sale to Genzyme in 2006. Prior to AnorMED, Mr. Adams was Chief Financial Officer of Epic Data International Inc., a TSX listed technology company. Mr. Adams holds a Bachelor of Commerce Degree from the University of British Columbia and qualified as a Chartered Accountant working in the audit and assurance practice of KPMG.
Angela Carter has over 15 years experience in in vitro diagnostics primarily in the areas of new Product Development, Clinical and Technical Support and Sales and Marketing. Her unique experience across multiple laboratory settings provides a unique perspective for driving and supporting technical sales and a keen understanding of the diagnostic landscape for multiple disease states. Ms. Carter holds an Honours degree in Biochemistry and has worked in research labs at Simon Fraser University, the University of British Columbia and the University of Toronto in the fields of molecular biology, proteomics and microarrays.
Previous to Response, Ms. Carter gained industry experience at Kinetek Biotechnology Ltd. where she focused on innovative diagnostics design for a novel cancer marker and at ID Biomedical where she worked in assay development for drug-resistant bacteria.
At Response she has held a number of positions including Quality Control and Analytical Development Manager and Manager of Worldwide Product Support and she is currently responsible for Global Sales and Marketing outside of China as well as new business development. Ms. Carter has played a key role in working strategically with our distribution partners to increase sales internationally and her in-depth clinical and technical knowledge is a key driver in continued sales growth at Response.
Megan Eastwood has over 20 years of experience working in a variety of manufacturing environments in Research and Development, Technical Transfer, Quality and Operations. Her experience has been in both large and small organizations ranging from Hillcross Pharmaceuticals Ltd. and AnorMED Inc., to Fit Foods and Norwood Packaging as the Director of Operations and Shearwater as General Manager. Her recent experience has provided her the cross-functional expertise to drive an organization to profitable growth. Her diverse background is unique and with this she brings extensive knowledge in change management: transitioning organizations through implementation of key strategic operational initiatives.
Ms. Eastwood is responsible for Response’s manufacturing and operations and will be leading the organizational change effort required for scaling the Company. Her greatest strengths include implementation of a results-driven culture, thriving on change and operational execution of clear tactical goals to achieve and implement a strategy. Her experience in the pharmaceutical industry and quality side of business will ensure the Company continues to maintain the highest quality standards for production of medical devices. Ms. Eastwood holds an Honours degree in Biology and serves as a member of the Canadian Manufacturer’s and Exporter’s Board of Directors.
Mark Nah has over 20 years experience in new Research and Development, Manufacturing and Production Support. He has experience in leading Research and Development teams through product life cycles, creating market-ready products from concept to commercialization. His experience in transfer of new products to manufacturing is invaluable in ensuring high quality manufacturing of medical device products efficiently and at a low cost.
Mr. Nah has wide technical experience spanning Software Development, Electronics and Mechanical engineering as well as cross-industry experience through work in the life science, semiconductor and defense-related industries. Having worked in companies like Fluidigm, developing microfluidics-based biomedical instruments and having held multiple positions at Kulicke & Soffa, developing high speed and high precision semiconductor assembly equipment, he is experienced at driving new technologies from the research phase through the product development life cycle to commercialization.
Mr. Nah holds a Master’s Degree in Biomedical Engineering and a Master’s Degree in Science and is responsible for Response’s Research and Development activities, as well as supporting the technology transfer into Manufacturing. His strengths include strong project management skills working cross-functionally across the organization as well an in-depth knowledge of new technologies and advances in research.
Anastasios Tsonis is a Chartered Accountant with nine years of experience in finance, accounting, and assurance. His experience includes financial analysis, cash management, managerial accounting, process improvement, and financial reporting. Before joining Response as a Corporate Controller in 2011, he worked in public accounting with Ernst & Young from 2006 through 2011, qualifying as a Chartered Accountant in their assurance practice in 2009.
In his current role, Mr. Tsonis is responsible for budgeting and forecasting, maintaining effective financial controls, completing the financial reporting requirements, managing treasury requirements, ensuring corporate compliance, and overseeing the day-to-day accounting and finance functions. In addition, Mr. Tsonis’ key strengths include a strategic business approach to financial analysis required to support strategic decision making and business strategy formulation. His knowledge of all aspects of the Company is key in being able to provide essential financial information to the board of directors and senior management.